放化疗联合卡瑞利珠单抗在食管癌患者中的有效性和安全性研究  

Efficacy and Safety Study of Radiotherapy Combined with Karelizumab in Patients with Esophageal Cancer

作　　者：丛龙飞 尹必辉 王卫星[1] CONG Longfei;YIN Bihui;WANG Weixing(Department of Oncology,Rudong County People's Hospital,Rudong 226400,Jiangsu,China)

机构地区：[1]如东县人民医院肿瘤科,江苏如东226400

出　　处：《系统医学》2025年第2期163-166,共4页Systems Medicine

摘　　要：目的探讨放化疗联合卡瑞利珠单抗在食管癌患者中的有效性和安全性。方法非随机选取2021年1月—2023年6月如东县人民医院收治的80例局部晚期或转移性食管癌的患者为研究对象,按照不同治疗方式进行分组。对照组(n=40)接受放疗联合铂类和紫杉类化疗,观察组(n=40)在对照组治疗基础上,增加卡瑞利珠免疫治疗。对比两组患者的肿瘤标志物水平、免疫功能指标、疾病控制和缓解情况、不良事件发生情况。结果治疗后,观察组的肿瘤标志物水平与对照组相比,水平较低,差异有统计学意义(P均<0.05)。治疗后,观察组免疫功能指标优于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组疾病控制率90.00%(36/40)高于对照组72.50%(29/40),差异有统计学意义(χ^(2)=4.021,P<0.05);观察组的客观缓解率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者各项不良事件发生率相比,差异无统计学意义(P均>0.05)。结论放化疗联合卡瑞利珠单抗治疗食管癌患者可降低肿瘤标志物水平,改善免疫功能,提高疾病控制率和客观缓解率,且不增加不良事件发生风险,具有良好的疗效和安全性。Objective To explore the effectiveness and safety of radiotherapy combined with karelizumab in esophageal cancer patients.Methods From January 2021 to June 2023,eighty patients with locally advanced or metastatic esophageal cancer admitted to Rudong County People's Hospital were non-randomly selected as the research objects.Grouped according to different treatment methods.The control group(n=40)was treated with radiotherapy combined with platinum and taxane chemotherapy,and the observation group(n=40)was treated with calory bead immunotherapy on the basis of the control group.The levels of tumor markers,immune function indexes,disease control and remission,and adverse events were compared between the two groups.Results After treatment,the level of tumor markers in the observation group was lower than that in the control group.and the differences were statistically significant(all P<0.05).After treatment,the immune function index of the observation group was better than that of the control group,and the differences were statistically significant(all P<0.05).After treatment,the disease control rate in observation group was 90.00%(36/40),which was higher than 72.50%(29/40)in the control group,and the difference was statistically significant(χ^(2)=4.021,P<0.05).The objective remission rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,there was no significant difference in the incidence of adverse events between the two groups(all P>0.05).Conclusion Radiotherapy and chemotherapy combined with karelizumab in the treatment of patients with esophageal cancer can reduce the level of tumor markers,improve immune function,improve disease control rate and objective remission rate,and do not increase the risk of adverse events,with good efficacy and safety.

关 键 词：放化疗 卡瑞利珠单抗 食管癌 免疫功能 

分 类 号：R735[医药卫生—肿瘤]